Cita APA (7a ed.)

C, X., F, X., R, W., Q, L., K, S., J, X., & L, L. (2021). Endostar Plus Apatinib Successfully Achieved Long Term Progression-Free Survival in Refractory Ovarian Cancer: A Case Report and Literature Review. Dove Medical Press.

Cita Chicago Style (17a ed.)

C, Xiao, Xu F, Wang R, Liang Q, Shen K, Xu J, y Liu L. Endostar Plus Apatinib Successfully Achieved Long Term Progression-Free Survival in Refractory Ovarian Cancer: A Case Report and Literature Review. Dove Medical Press, 2021.

Cita MLA (8a ed.)

C, Xiao, et al. Endostar Plus Apatinib Successfully Achieved Long Term Progression-Free Survival in Refractory Ovarian Cancer: A Case Report and Literature Review. Dove Medical Press, 2021.